Transform patient genomic and clinical profiles into actionable risk stratification, treatment recommendations, and personalized therapeutic strategies. Integrates germline genetics, somatic alterations, pharmacogenomics, pathway biology, and clinical evidence to produce a quantitative risk score with tiered management recommendations.
| Cancer + mutations + stage | "Breast cancer, BRCA1 mut, ER+, HER2-, stage II" | disease=breastcancer, mutations=[BRCA1], biomarkers={ER:+, HER2:-}, stage=II | | Metabolic + biomarkers + PGx | "T2D, HbA1c 8.5, CYP2C19 2/2" | disease=T2D, biomarkers={HbA1c:8.5}, pgx={CYP2C19:poormetabolizer} |
| CVD risk profile | "High LDL 190, SLCO1B15, family hx MI" | disease=CVD, biomarkers={LDL:190}, pgx={SLCO1B1:5}, familyhx=positive | | Rare disease + variant | "Marfan, FBN1 c.4082G>A" | disease=Marfan, mutations=[FBN1 c.4082G>A], diseasetype=rare | | Neuro risk | "Alzheimer risk, APOE e4/e4, age 55" | disease=AD, genotype={APOE:e4/e4}, clinical={age:55} |